PL3212208T3 - Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia - Google Patents

Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia

Info

Publication number
PL3212208T3
PL3212208T3 PL15788001T PL15788001T PL3212208T3 PL 3212208 T3 PL3212208 T3 PL 3212208T3 PL 15788001 T PL15788001 T PL 15788001T PL 15788001 T PL15788001 T PL 15788001T PL 3212208 T3 PL3212208 T3 PL 3212208T3
Authority
PL
Poland
Prior art keywords
reuteri
prevention
treatment
early life
microbiota dysbiosis
Prior art date
Application number
PL15788001T
Other languages
English (en)
Inventor
Clara Lucia Garcia-Rodenas
Bernard Berger
Catherine NGOM-BRU
Melissa LEPAGE
Tara NEVILLE
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51897072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3212208(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of PL3212208T3 publication Critical patent/PL3212208T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pediatric Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PL15788001T 2014-10-29 2015-10-29 Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia PL3212208T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14190941 2014-10-29
PCT/EP2015/075164 WO2016066763A1 (en) 2014-10-29 2015-10-29 Use of l. reuteri for recovery of microbiota dysbiosis in early life
EP15788001.4A EP3212208B1 (en) 2014-10-29 2015-10-29 Use of l. reuteri for prevention or treatment of microbiota dysbiosis in early life

Publications (1)

Publication Number Publication Date
PL3212208T3 true PL3212208T3 (pl) 2021-09-06

Family

ID=51897072

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15788001T PL3212208T3 (pl) 2014-10-29 2015-10-29 Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia

Country Status (17)

Country Link
US (2) US11369646B2 (pl)
EP (1) EP3212208B1 (pl)
KR (2) KR102606971B1 (pl)
CN (2) CN116650541A (pl)
AU (1) AU2015340605B2 (pl)
BR (1) BR112017005612A2 (pl)
CA (1) CA2960337C (pl)
CL (1) CL2017000850A1 (pl)
DK (1) DK3212208T3 (pl)
ES (1) ES2870425T3 (pl)
MX (1) MX2017005497A (pl)
MY (1) MY186733A (pl)
PH (1) PH12017500334A1 (pl)
PL (1) PL3212208T3 (pl)
RU (1) RU2723687C2 (pl)
WO (1) WO2016066763A1 (pl)
ZA (1) ZA201703635B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12005085B2 (en) * 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
JP6754694B2 (ja) 2014-03-06 2020-09-16 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル プロバイオティクス製剤および使用のための方法
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US20180171389A1 (en) * 2015-06-16 2018-06-21 Murdoch Childrens Research Institute Method of treating crohn's disease
US20180207067A1 (en) 2015-07-14 2018-07-26 Research Institute at Nationwide Children's Hospit al Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
PL3445380T3 (pl) * 2016-04-19 2024-07-15 Genome Research Limited Bakterioterapia
CN109475169A (zh) 2016-07-01 2019-03-15 进化生物系统股份有限公司 促进哺乳动物免疫系统成熟的方法
AU2017324759B2 (en) * 2016-09-07 2022-07-28 Société des Produits Nestlé S.A. Nutritional compositions for infants and/or young children comprising oligosaccharides
EP3645023B1 (en) * 2017-06-30 2022-09-14 N.V. Nutricia Synbiotic composition for preventing hyperinsulinemia and insulin resistance
US11524019B2 (en) 2017-08-21 2022-12-13 Glycom A/S Synthetic composition for reducing allergy symptoms
EP3716984B1 (en) 2017-11-30 2024-03-20 Glycom A/S Mixture of hmos for treating wheat sensitivity
GB2573538B (en) * 2018-05-09 2023-01-04 Mjn Us Holdings Llc Pediatric nutritional compositions and methods for infants delivered by C-section
US20210290701A1 (en) * 2018-08-03 2021-09-23 Research Institute At Nationwide Children's Hospital Prenatal probiotic formulations
WO2020033440A1 (en) * 2018-08-10 2020-02-13 The Regents Of The University Of California Methods and compositions for treating and preventing inflammatory diseases
US20230141737A1 (en) * 2018-10-22 2023-05-11 Research Institute At Nationwide Children's Hospital Compositions and methods for preventing and treating antibiotic induced pathologies using probiotics in the biofilm state
MX2021007599A (es) * 2018-12-19 2021-10-13 Healthy Cow Corp Composiciones probióticas listas para utilizar y usos de las mismas.
FR3093427B1 (fr) * 2019-03-05 2021-03-05 Mativa Tech Composition pour son utilisation dans la prévention et/ou le traitement de la dysbiose
US20220293275A1 (en) * 2019-06-11 2022-09-15 CJ Bioscience. Inc Method for detecting gut dysbiosis of infant
CN110591945A (zh) * 2019-09-06 2019-12-20 吉林大学 一株用于预防溃疡性结肠炎的优良罗伊氏乳杆菌
KR102529206B1 (ko) * 2019-12-20 2023-05-08 충북대학교 산학협력단 신규한 락토바실러스 루테리 ｄｂ２ 균주 및 이의 용도
CN111254090B (zh) * 2019-12-30 2021-11-05 杭州娃哈哈科技有限公司 一株具有减肥功能的罗伊氏乳杆菌及其应用
CN111265553B (zh) * 2020-01-23 2021-06-22 湖南菲勒生物技术有限公司 一株母乳来源罗伊氏乳杆菌调节母婴免疫功能的应用
CN113073066B (zh) * 2021-04-16 2022-01-04 段云峰 罗伊氏乳杆菌及其应用、组合物、药物和食品
CN113180109B (zh) * 2021-04-16 2022-02-18 段云峰 罗伊氏乳杆菌在制备预防或治疗发育障碍类疾病产品中的应用
FR3126869A1 (fr) 2021-09-16 2023-03-17 Gozen K. K. Japan Composition pharmaceutique comprenant des métabolites issus de la bactérie Bacillus subtilis Gozen GZN-08 isolée de Camellia sinensis et modulant la réponse immunitaire.
CN114107088B (zh) * 2021-10-20 2023-07-21 山西大学 一种罗伊氏乳杆菌lrsy523及其应用
CN113943687B (zh) * 2021-12-21 2022-02-22 山东中科嘉亿生物工程有限公司 一种改善溃疡性结肠炎的罗伊氏乳杆菌jylb-291及其应用
CN114990004B (zh) * 2022-04-19 2023-09-15 尚品健康科技(青岛)有限公司 一种分泌型免疫球蛋白a包裹态罗伊氏乳杆菌及防治妊娠糖尿病的应用
WO2024080918A1 (en) * 2022-10-13 2024-04-18 Baylor College Of Medicine Secretin inducing bacteria
CN117982544B (zh) * 2024-04-03 2024-07-05 哈尔滨葵花药业有限公司 一株罗伊氏粘液乳杆菌Glory LR15在调节肥胖型哮喘产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
AU2009253281A1 (en) * 2008-05-27 2009-12-03 Nestec S.A. Probiotics to improve gut microbiota
EP2127661A1 (en) 2008-05-27 2009-12-02 Nestec S.A. Probiotics to improve gut microbiotica
EP2147678A1 (en) * 2008-07-21 2010-01-27 Nestec S.A. Probiotics to increase IgA secretion in infants born by caesarean section
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
TW201438719A (zh) * 2012-12-18 2014-10-16 Abbott Lab 改善壓力症狀之母乳寡糖
US20170216375A1 (en) * 2014-05-20 2017-08-03 Biogaia Ab Neonatal Microbiome Supplementation

Also Published As

Publication number Publication date
KR20220163503A (ko) 2022-12-09
US20220331380A1 (en) 2022-10-20
CL2017000850A1 (es) 2017-11-03
ZA201703635B (en) 2019-06-26
AU2015340605B2 (en) 2021-06-24
RU2017118358A (ru) 2018-11-29
US11369646B2 (en) 2022-06-28
US11701397B2 (en) 2023-07-18
MX2017005497A (es) 2017-09-15
AU2015340605A1 (en) 2017-03-16
WO2016066763A1 (en) 2016-05-06
US20180280454A1 (en) 2018-10-04
CN116650541A (zh) 2023-08-29
EP3212208A1 (en) 2017-09-06
DK3212208T3 (da) 2021-05-17
RU2017118358A3 (pl) 2019-03-05
BR112017005612A2 (pt) 2017-12-12
RU2723687C2 (ru) 2020-06-17
CN106794207A (zh) 2017-05-31
ES2870425T3 (es) 2021-10-27
CA2960337C (en) 2022-04-05
KR20170072879A (ko) 2017-06-27
EP3212208B1 (en) 2021-03-03
KR102606971B1 (ko) 2023-11-30
CA2960337A1 (en) 2016-05-06
MY186733A (en) 2021-08-15
PH12017500334A1 (en) 2017-07-17

Similar Documents

Publication Publication Date Title
PL3212208T3 (pl) Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia
SG11201703298SA (en) Activated bifidobacteria and methods of use thereof
HUE056596T2 (hu) Módosított biológiai szabályozó szer és ennek alkalmazásai
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
HK1243055A1 (zh) 用於抗蠕蟲治療的化合物
PL3302519T3 (pl) Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu ostrej choroby przeszczep przeciwko gospodarzowi
IL247435A0 (en) Pyridazine derivatives for use in the prevention of or treatment of ataxic disorder
ZA201701426B (en) Compounds for use in anthelminthic treatment
GB201404372D0 (en) Assay and treatment
SI3197556T1 (sl) Sestavek za preprečevanje in/ali zdravljenje alergijskih simptomov
PT3232789T (pt) Comprimidos para o tratamento e desinfeção da água
PL3194968T3 (pl) Wykrywanie i traktowanie bydlęcego wirusa opryszczki
PL3232998T3 (pl) Urządzenie medyczne do wykonywania ileostomii i/albo jejunostomii
GB2524474B (en) Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes
IL252493A0 (en) Compounds for use in the prevention or treatment of cancer
IL249152A0 (en) Botulinum toxin for use in the treatment of paratonia
EP3104940A4 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
GB201415876D0 (en) Methods for the treatment and prevention of Ebola
GB201511772D0 (en) Improvements in the treatment of ash
ZA201404780B (en) Composition for use in treatment of diabetes
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes
TH1501006525A (th) สารหรือวิธีการสำหรับการรักษาและ/หรือการป้องกันการใช้พลังงานหมดเร็วขึ้น และ/หรือการทำหน้าที่ใช้พลังงานลดลง